文献速递治疗药物监测与药物基因组学特殊人群用药

肝移植受者与供肝CYP3A基因型差异与他克莫司剂量调整

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
PubMed 文献 · Br J Clin Pharmacol · 2019-06-12

本文报告一例非洲裔美国女性肝移植受者,因受者与供肝的CYP3A4/5多态性差异导致他克莫司谷浓度难以达标。病例提示对肝移植受者和供肝进行基因分型可能为预测移植后他克莫司代谢提供依据。

要点

  • 他克莫司治疗窗窄,需常规监测谷浓度(C0)以达最佳治疗水平。
  • 他克莫司经肝脏和肠道CYP3A4和CYP3A5代谢。
  • 受者与供肝CYP3A4/5多态性差异可致他克莫司浓度难以达标。

核心结论

  • 肝移植受者与供肝的CYP3A4/5多态性差异可导致他克莫司浓度难以达标。
  • 对受者和供肝进行基因分型可能为预测移植后他克莫司代谢提供数据。

研究设计与样本

  • 病例报告:一例接受肝移植的非洲裔美国女性。

主要发现

  • 因受者与供肝CYP3A4/5多态性差异, adequate他克莫司水平难以实现。

临床怎么用

  • 他克莫司治疗窗窄,所有接受他克莫司的患者需监测谷浓度(C0)以达最佳治疗水平。
  • 肝移植受者与供肝的CYP3A基因分型可能有助于预测移植后他克莫司代谢。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tacrolimus (Tac) is well established as main immunosuppressant in most immunosuppressive regimens in solid organ transplantation. Due to the narrow therapeutic window, pre dose Tac levels (C0) are monitored in all patients receiving Tac to reach optimal therapeutic levels. Tac is metabolized in the liver and intestine by the cytochrome P450 3A (CYP3A) isoforms CYP3A4 and CYP3A5. We present a case of an African American woman who underwent a liver transplantation in which adequate Tac levels were difficult to accomplish due to differences in cytochrome P450 3A4/5 (CYP3A4/5) polymorphisms of the transplant recipient and the donor liver graft. This case report highlights that genotyping the liver transplant recipient and the donor liver graft might provide data which could be used to predict the tacrolimus metabolism post transplantation.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Berger FA, Mulder MB, Ten Bosch-Dijksman W, et al. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose. Br J Clin Pharmacol. 2019. PMID: 31190414. doi:10.1111/bcp.13958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。